Immunome Portfolio News

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

By WebmasterOctober 19, 2023December 12th, 2024No Comments

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

– Seasoned biotechnology executive and board-certified physician in medical oncology joins executive team as Immunome advances growing pipeline of cancer therapies

See more here

Previous PostENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023
Next PostVenatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023

Next PostVenatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract